Skip to main content
Premium Trial:

Request an Annual Quote

BioReference Laboratories' OnkoSight

BioReference Laboratories has introduced two sequencing tests that it believes will enhance the information that physicians can obtain from tumor samples when treating oncology patients. The company will offer this next-generation sequencing program, called OnkoSight, through its GenPath Oncology business unit. The custom-designed NGS panels ar OnkoSight Solid, consisting of 31 genes for solid tumors; and OnkoSight Myeloid, comprising 37 genes for myeloid disorders. The company said that six additional focused panels are available based on tumor type: lung, colon, melanoma, myelodsyplastic syndromes, acute myeloid leukemia, and myeloproliferative neoplasms.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.